Bipartisan Support For Comparative Efficacy Policy Likely To Grow - McClellan
This article was originally published in The Pink Sheet Daily
Executive Summary
Increasing interest in demonstrating safety, efficacy and value of medications will drive development of policies around comparative evidence, the former FDA head predicts.